Generate Biomedicines (NASDAQ:GENB) Hits New 1-Year High – Should You Buy?

Generate Biomedicines Inc (NASDAQ:GENB) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $15.32 and last traded at $15.1680, with a volume of 97984 shares traded. The stock had previously closed at $14.46.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on GENB shares. Wall Street Zen upgraded Generate Biomedicines to a “hold” rating in a report on Saturday, March 14th. Guggenheim initiated coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $30.00 price target on the stock. The Goldman Sachs Group initiated coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price target on the stock. Morgan Stanley initiated coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating and a $20.00 price target on the stock. Finally, HC Wainwright initiated coverage on Generate Biomedicines in a research report on Monday, April 13th. They set a “buy” rating and a $16.00 price target on the stock. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Generate Biomedicines presently has an average rating of “Moderate Buy” and a consensus target price of $23.20.

Generate Biomedicines Stock Performance

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.